MRM Health

MRM Health is a Belgian clinical-stage biotech pioneering a novel approach to live biotherapeutic products (LBPs) through its disruptive CORAL® platform. This technology enables the rational design and scalable manufacturing of optimized, disease-focused microbial consortia, aiming for superior efficacy and safety. The company has demonstrated clinical proof-of-concept in IBD, is advancing a pipeline in other inflammatory and immuno-oncology indications, and is backed by a strong syndicate of strategic and financial investors. Its end-to-end capabilities and academic partnerships position it as a key player in the evolving microbiome therapeutics field.

Proprietary CORAL® platform for the bioinformatics-guided discovery, optimization, and single-batch GMP manufacturing of defined, multi-strain microbial consortia (Optimized Consortia) as a single Drug Substance.

MRM Health competes in the dynamic microbiome therapeutics space against companies developing single-strain drugs, defined consortia, and fecal microbiota transplants. Its key differentiators are the rational optimization of consortia for specific diseases and its breakthrough single-batch manufacturing process, which aims to solve critical scalability and consistency challenges faced by earlier approaches.